Uncategorized Archives - Page 14 of 134

TuesdayMar 26, 2024 9:00 am

Clene Inc. (NASDAQ: CLNN) Announces Operational Highlights for Lead Therapeutic Candidate for ALS and MS

Clene’s recently released 2023 financial and operational updates highlight the company’s developments for the treatment of amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis CNM-Au8(R) functions as a neuroprotective and remyelinating therapy in neurodegenerative diseases Recent data from the randomized, double-blind, placebo-controlled HEALEY-ALS Platform Trial and its open-label extension, reported by Clene in December 2023, revealed encouraging outcomes on survival and delayed clinical worsening Clene recently provided perspectives on its achievements and the development path for CNM-Au8(R) during its participation in the 36th Annual ROTH Conference, which was held March 18-19, 2024 Clene (NASDAQ: CLNN) and its wholly owned subsidiary Clene…

ThursdayMar 21, 2024 10:30 am

PaxMedica Inc. (NASDAQ: PXMD) Developing Pipeline to Address Unmet Needs in Autism Spectrum Disorder via Suramin Sodium

Autism (“ASD”) is a global problem, with no generally accepted treatment. In the UK alone, between 1998 and 2018, research has found a greater than 780% increase in the number of autism cases PaxMedica is focused on the development of novel anti-purinergic therapies (“APTs”) for the treatment of ASD and other serious conditions with intractable neurologic symptoms The ASD therapeutics market was valued at $2.01 billion in 2023 and is expected to reach $3.42 billion by 2030, growing at a CAGR of 7.9% There is currently no approved pharmacologic treatment targeting the cause and symptoms. Current treatments only address the…

MondayMar 18, 2024 10:30 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Welcomes Proven Commercialization Leader to Its Board of Directors

CNS Pharmaceuticals recently appointed Amy Mahery, a biotech commercialization leader, to its Board of Directors Ms. Mahery brings over 20 years’ experience, having worked with small and large companies, and has held diverse commercial leadership roles in the U.S. and globally The company believes Ms. Mahery’s guidance, insight, and vast pharma industry network will indeed be invaluable as the company advances Berubicin, its flagship drug candidate, toward completion of its global potentially pivotal clinical trial and potential regulatory approval The company recently completed the enrollment of patients in its potentially pivotal global clinical trial Ms. Mahery believes Berubicin represents an…

MondayMar 11, 2024 10:30 am

Astiva Health Inc. — Pioneering a New Era in Aging Healthcare

Astiva Health is revolutionizing patient involvement in healthcare, particularly for the aging population Beyond offering healthcare services, Astiva is dedicated to creating a supportive health community With patients at the center, Astiva Health is transforming aging healthcare into a proactive, participatory experience The United States is in the midst of a global demographic shift toward an aging population, with the U.S. Census Bureau projecting that by 2034, adults aged 65 and older will outnumber children under the age of 18 for the first time in U.S. history (https://ibn.fm/yGoyH). With this shift, the demand for a more holistic approach to healthcare…

FridayMar 08, 2024 9:45 am

PaxMedica Inc. (NASDAQ: PXMD) Pursues Autism Treatment as Diagnostic App Shows Promise to Effective ASD Diagnosis

One in 36 children are diagnosed with autism spectrum disorder (“ASD”) – with ASD four times more common among boys than girls The SenseToKnow app accurately predicted eventual autism diagnoses in a group of 475 children – according to the study, performance was similar across sex, race, and ethnicity PaxMedica is leveraging historical data on the drug suramin to fund trials aimed at treating Autism Spectrum Disorder and Fragile X-Associated Tremor/Ataxia Syndrome According to the CDC, about 1 in 36 children are diagnosed with autism spectrum disorder (“ASD”) – with ASD four times more common among boys than girls (https://ibn.fm/06kly).…

TuesdayMar 05, 2024 9:45 am

Sigyn Therapeutics Inc. (SIGY) Therapeutic Candidates to Overcome Limitations in Healthcare

Sigyn Therapeutics is developing four medical device candidates – Sigyn Therapy(TM), ChemoPrep(TM), ChemoPure(TM), and ImmunePrep(TM) – designed to overcome current therapeutic limitations in healthcare Sigyn Therapy(TM), the company’s lead product candidate, is a single-use disposable device to treat life-threatening inflammatory conditions that are beyond the reach of drugs ChemoPrep(TM) is designed to optimize the tumor-site delivery of chemotherapy, while ChemoPure(TM) intends to reduce the toxicity of chemotherapy by sweeping off-target chemotherapy out of the bloodstream ImmunePrep(TM) is designed to reduce the presence of circulating drug decoys that interfere with the delivery of immunotherapeutic antibodies to treat cancer Medical technology company Sigyn…

MondayMar 04, 2024 10:30 am

Astiva Health Inc. CEO Featured Podcast Guest, Talks Commitment to Help Patients Enjoy ‘Active, Healthy and Meaningful’ Lives

In addition to providing full medical-care prescription drugs, Astiva focuses on providing rich supplemental benefits to enrollees CEO explains that “effective healthcare hinges largely on patient involvement” Astiva’s recent expansion is a crucial step in extending invaluable benefits and commitment to quality healthcare to a growing, diverse population Astiva Health CEO Dr. Tri Nguyen was the featured guest in a recent Bell2Bell Podcast release (https://ibn.fm/0Rufk). During the podcast, Nguyen talked provided an in-depth look at how Astiva Health is reshaping healthcare delivery, including an overview of the company’s commitment to patient involvement in healthcare and highlights the company’s innovative strategies in offering comprehensive…

TuesdayFeb 27, 2024 12:00 pm

Astiva Health Inc. Championing Culturally Sensitive Healthcare for Aging Asian American Population

By 2060, the older Asian population in the U.S. is expected to reach 8.5 million, making up 9% of the country's elderly demographic, signaling a significant increase from 4% in 2014 Astiva Health is leading the charge in creating essential healthcare solutions tailored for this expanding demographic, demonstrating a deep understanding of their unique healthcare needs Astiva Health has introduced groundbreaking programs, including language-specific healthcare services and wellness initiatives, specifically designed for the diverse aging Asian American community Astiva Health is working serve the Asian American community, which is undergoing a considerable demographic shift, with a growing segment of the…

TuesdayFeb 27, 2024 11:15 am

Astrotech Corp. (NASDAQ: ASTC) Reports 512% Jump in YTD Revenue

Astrotech reported financial results for the quarter ended December 31, 2023, recording year-to-date revenue of $1,540,000 The company attributed the growth to the successful fulfillment of two significant purchase orders for the TRACER 1000(TM), the world’s first mass spectrometer-based explosive trace detectors (“ETD”), to customers in Romania Astrotech is focused on commercializing its innovative platform mass spectrometry technology through its wholly owned subsidiaries 1st Detect Corp., AgLAB Inc., Pro-Control Inc., and BreathTech Corp. The company and its subsidiaries are positioned to capitalize on burgeoning markets, including the global mass spectrometry market, expected to grow from an estimated $6.77 billion in…

TuesdayFeb 27, 2024 10:30 am

Sigyn Therapeutics Inc. (SIGYD) Completes Reverse Stock Split, Releases Year-End Financial Report for 2023

Sigyn's common stock, temporarily trading under the ticker symbol "SIGYD", is set to revert back to its historic symbol "SIGY" on February 29, 2024. The company, as part of its 2023 Year-End Report, summarized its development of medical technologies that target to overcome clearly defined limitations in global health. During 2023, Sigyn expanded its line-up of medical technologies designed to enhance the benefit of cancer therapies. The company’s cancer treatment pipeline now includes ImmunePrep(TM), ChemoPrep(TM), and ChemoPure(TM). The company believes the successful clinical advancement of Sigyn Therapy(TM) to treat pathogen-associated conditions beyond the reach of drugs, may offer a…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Category: Uncategorized

Clene Inc. (NASDAQ: CLNN) Announces Operational Highlights for Lead Therapeutic Candidate for ALS and MS

PaxMedica Inc. (NASDAQ: PXMD) Developing Pipeline to Address Unmet Needs in Autism Spectrum Disorder via Suramin Sodium

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Welcomes Proven Commercialization Leader to Its Board of Directors

Astiva Health Inc. — Pioneering a New Era in Aging Healthcare

PaxMedica Inc. (NASDAQ: PXMD) Pursues Autism Treatment as Diagnostic App Shows Promise to Effective ASD Diagnosis

Sigyn Therapeutics Inc. (SIGY) Therapeutic Candidates to Overcome Limitations in Healthcare

Astiva Health Inc. CEO Featured Podcast Guest, Talks Commitment to Help Patients Enjoy ‘Active, Healthy and Meaningful’ Lives

Astiva Health Inc. Championing Culturally Sensitive Healthcare for Aging Asian American Population

Astrotech Corp. (NASDAQ: ASTC) Reports 512% Jump in YTD Revenue

Sigyn Therapeutics Inc. (SIGYD) Completes Reverse Stock Split, Releases Year-End Financial Report for 2023

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search